Elevance’s $100M IPO: The 10-Minute Version

Jim Lane Like to quickly understand the surge in renewable chemicals and one of the hottest companies in the hottest sector of the bioconomy? Here’s our 10-minute version of the IPO from Elevance Renewable Sciences. Complete with the risks, translated into English from the original SEC-speak. In Illinois, Elevance Renewable Sciences filed its S-1 registration statement relating to a proposed $100 million initial public offering. The number of shares to be offered and the price range for the offering have not yet been determined. The company indicated that it has apply to list the stock on NASDAQ under the ERSI symbol. The...
Amyris logo

Biofuels & Biobased Earnings Roundup: Amyris

by Jim Lane The Top Line. In California, Amyris (AMRS) reported Q2 GAAP revenue for the second quarter of 2018 of $24.8 million, compared with $25.7 million for the second quarter of 2017. Grants and collaborations revenue was $11.4 million for the second quarter of 2018 compared with $10.3 million for the year-ago period. The company noted that Q2 revenue was $24.8 million compared with the same period in 2017 of $21.7 million when adjusted for the low margin product sales on contracts assigned to DSM (DSM.AS). This reflects 15% growth on an absolute basis. GAAP net loss for the first half was $89.1...

Biofuels M&A: 2017 Review and Outlook

by Bruce Comer, Ocean Park Advisors More industry players chose to develop and build new capacity rather than buy plants The North American biofuels industry experienced the fewest merger and acquisition transactions in recent history in 2017. There were only six M&A transactions, with a total estimated value of more than $100 million. They involved eight plants with 297 million gallons per year (MGPY) of production capacity. Half of these deals were for non-operating plants. A fourth deal was for a sub-scale demonstration plant. Contributing to the limited deal flow, two historically active acquirers, Green Plains and REG, did not close...

American Refining Group Joins Amyris And Cosan In Renewable Base Oil JV

Jim Lane IIn California, American Refining Group has committed to a 33.3% equity investment into Novvi , a joint venture of Amyris (AMRS) and Cosan (CZZ). Both Amyris and Cosan will continue to hold share ownership stakes in Novvi, together with ARG. It’s not a tiny market by any means. The global markets for base oils and lubricants, are expected to reach $42 billion and $70 billion in size, respectively, by 2020, according to Amyris. For ARG: Why Novvi, why now? Think novel performance. It goes in two directions. First, there’s low-carbon performance customers want...

Biobased and Biofuel Investments: A System

Jim Lane A Biofuels and Biobased investment primer: An 18-combination, 8-character system for classifying bio investments Here’s our investment primer on how to size up the risks and the rewards and tune them to meet your goals. And, a system for organizing opportunities. So, you’re thinking about investing in bio? Here’s the good news – you’re not alone. Here’s the bad news – you’re not alone. There are retail, private equity, hedge fund, sovereign wealth, strategic, grower, VC and institutional investors snooping around too, and making active investments. For one thing, carbon’s making a comeback as the...
vaccine

Amyris Launches Leading Hand Sanitizer and Receives Initial Positive Result for Vaccine Adjuvant

by Jim Lane In California comes the news that synthetic biology leader Amyris (AMRS) is stepping out to help fight COVID-19. Amyris may be more well known for its sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, but as you all know, things have changed a lot over the last few months and Amyris is now launching a hand sanitizer to help address the high demand triggered by COVID-19. Additionally, the company has completed initial testing of a leading vaccine adjuvant. Amyris is leveraging its existing capabilities to fast track the availability of a safe...

Lower Revenues at Solazyme, But Also Lower Losses and New Customers

Jim Lane In California, Solazyme (SZYM) reported Q2 revenues of $11.7M compared with $15.9M in Q22014. GAAP net loss was $37.2 million for Q2 2015, compared to net loss of $42.9M in the prior year period. The company said that “year over year decline in revenues was due to expected decreases in funded program revenue as well as in product revenue due to the timing of certain Algenist sales activities and slower than anticipated adoption rates for Encapso.” The market responded to the results by slashing the stock price 20 percent in Friday trading. Analyst reaction was more positive,...
Gevo renewable fuel and chemical plant

Gevo’s Glow

Specialty chemicals developer Gevo, Inc. (GEVO:  Nasdaq) is celebrating a string of market wins for its renewable chemicals and fuels.  Since its beginning thirteen years ago this month, Gevo has been doggedly perfecting its synthetic biology and chemical technologies and turning it into products that are in demand by consumers and industry.  Last week shareholders were treated to an announcement by the U.S. Environmental Protection Agency (EPA) raising the amount of isobutanol for on-road use to 16% blend level from 12.5%.  As a producer of renewable isobutanol Gevo will be a direct beneficiary of the EPA action. Following directly on the heels of that news,...

Gevo Begins To Ship Missing Link For 100% Renewable Plastic Bottles

Jim Lane From Colorado, news has arrived that Gevo (GEVO) is now selling paraxyleme to Toray (TRYIF), one of the world’s leading producers of fibers, plastics, films, and chemicals. It’s producing PX from isobutanol, one of its three molecules in production (the others are jet fuel and iso-ocrane) at its complex in Silsbee, Texas. Toray expects to produce fibers, yarns, and films from Gevo’s PX. While any new molecule attached to a major customer relationship is always big news for any producer this has special significance. Let’s review exactly why....

Corbion Bids To Acquire TerraVia

Corbion Bids To Acquire TerraVia In California, Corbion has made a $20M stalking horse stock and asset purchase bid for TerraVia (TRVA). The purchase agreement provides TerraVia with a binding bid of $20 million in cash along with the assumption of certain liabilities, which is subject to higher or otherwise better offers. As part of the transaction, Corbion will be assuming the ongoing financial obligations of the business and its joint venture ownership, therefore the total financial commitment is expected to be in excess of the cash purchase price. Through this proposed transaction, TerraVia employees, who bring with them a wide...

Amyris: Biochemical Bargain?

Industrial bio-chemical developer Amyris, Inc. (AMRS:  Nasdaq) has been in the headlines recently  -  some pointing to solid fundamental progress, others ‘not so much.’  Amyris recently announced a new relationship with Givaudan (GIVN: VX), a supplier of active ingredients for cosmetics.  The two have agreed to collaborate in research and development on proprietary fragrances.  Earlier this month Amyris announced the launch by Takasago International Corporation (TYO:  4914) of a new fragrance created with Amyris’ technology. Cosmetics and fragrances present large market opportunities and the strength of demand for personal care products supports strong profit margins.  The relationships are likely...

Why Traffic Lights Are Turning Green For BioAmber

Jim Lane As many technologies pivot or delay, one train keeps chugging on its route to biosuccinic acid, and markets like BDO, resins and polyols. What is it about the business model that keeps on working? What can every integrated biorefinery learn from its approach? In Minneapolis, BioAmber (BIOA) just announced a contract to supply a minimum of 80% of PTTMCC Biochem’s total bio-succinic acid needs until the end of 2017. PTTMCC Biochem is a joint venture established by Mitsubishi Chemical and PTT, Thailand’s largest oil and gas company, to produce and sell polybutylene succinate (PBS),...

Jobs at Gevo

by Debra Fiakas CFA Management teams at the helm of public companies often shade the realities of their competitive or strategic situation, alternately painting better circumstances or downplaying declining fortunes.  There are myriad ways of giving management’s guidance a reality check.  Renewable bio-chemicals developer Gevo, Inc. (GEVO:  Nasdaq) is on my “watch list” as one of the more interesting companies in the Beach Boys Index.    Gevo’s financial results missed the consensus estimate in both the March and June 2012 quarters, but management made claims of important victories.  Gevo has won important decisions in the disagreement...

BioAmber’s Sarnia Plant Operating At Commercial Scale

Jim Lane Ultra-secret yeast tech also exceeding expectations in yield, productivity and quality, BioAmber reports. Baby Sarnia checks in at 60 million pounds, no ounces, doing fine. In Canada, BioAmber’s (BIOA) Sarnia joint venture with Mitsui & Co. Ltd. has begun shipping bio-succinic acid to customers and is operating its manufacturing process at commercial scale, meeting a significant company milestone, the company said. Yeast biotechnology exceeds performance targets BioAmber has confirmed the performance of its proprietary yeast in the production fermenters in Sarnia. The fermentation performance achieved is significantly above the initial targets set for...

Amyris: 90 Days To Build The Future

Jim Lane In California, Amyris (AMRS) reported Q1 revenues of $13.0M compared with $8.8M for Q1 2016, and touted the “significant increase in product sales, primarily in the personal care and health and nutrition markets, offset by a slight decline in collaboration revenue.” Collaboration revenues contributed $4.7M and product sales added $8.3M for the quarter. Big Q1 miss vs analyst expectations As Jeff Osborne at Cowen & Co noted, “Amyris reported revenue of $13.0mn, well below our estimate of $37.1mn due to much lower collaboration payments than we had anticipated. Management has highlighted that these payments can...

Leather Without The Cow

Flokser launches Artificial Leather based on DuPont Tate & Lyle, BioAmber ingredients Jim Lane In Canada, BioAmber (BIOA) announced that the Flokser Group has successfully developed an innovative artificial leather fabric using bio-based materials supplied by DuPont (DD) Tate & Lyle Bio Products and BioAmber. Flokser has launched this new synthetic leather fabric under its SERTEX brand. The novel fabric comprises a polyester polyol made from BioAmber’s Bio-SA bio-based succinic acid and DuPont Tate & Lyle Bio Products’ Susterra bio-based 1,3-propanediol. Flokser’s artificial leather fabric has 70% renewable content and delivers improved performance. It provides better scratch resistance...
Close Bitnami banner
Bitnami